RICHMOND, Va., Oct. 30, 2001 (PRIMEZONE) -- Investors interested in learning more about developments and breakthroughs against cancer are invited to listen to Informed Investors' 5th annual Cancer Stocks Forum on Tuesday, Dec. 4, 2001 via the Internet.
This annual event showcases companies at the forefront in the cancer battle. The virtual Forum is accessible over the Internet via www.informedinvestors.com. It runs from 8:30 a.m. - 1 p.m. EST. There is no cost to investors. The event will also be archived and available for investors after December 4 on www.vcall.com and www.investorconference.com.
Senior executives will discuss their company's current prospects and overview their business strategies in the same fashion they do for institutional investors. The segments are approximately 30 minutes each and include PowerPoint presentations. Also, investors are invited to e-mail questions to executives.
The keynote speaker is Alan Auerbach, Vice President/Research Analyst at Wells Fargo Van Kasper, where he specializes in the biotechnology and biomedical sectors.
Heading the list of presenting companies is Genentech (NYSE:DNA), the first public biotechnology company and the second largest after Amgen. South San Francisco-based Genentech recently reported higher earnings on the strength of its two cancer drugs, Rituxan for non-Hodgkin's lymphoma and breast cancer drug Herceptin. Third-quarter sales of Rituxan rose 80 percent to $212.8 million from $117.9 million a year earlier, while sales of Herceptin rose 16 percent to $83.9 million from $72.6 million.
Another presenting company is Genzyme Molecular Oncology (Nasdaq:GZMO) a division of Genzyme Corp. GZMO recently announced issuance of an important patent for the discovery of novel, synthetic peptides and pharmaceutical compositions useful as therapeutic melanoma vaccines. It was the first patent issued based upon its SPHERE Technology. The company also has more than 250 issued and pending patents domestically and worldwide, approximately 40 specific to antigen discovery.
Dendreon Corporation (Nasdaq:DNDN) of Seattle is on the docket as well. Recently, Dendreon announced that it has enlisted Gambro Healthcare, a wholly owned U.S. subsidiary of Gambro AB, to collaborate with it to commercialize Dendreon's lead product Provenge and other therapeutic cancer vaccines.
Other companies scheduled to present include: AEterna Labs, Aastrom Biosciences, Genzyme Molecular Biology, NeoRx Corp., Onyx Pharmaceuticals, and Targeted Genetics.
Informed Investors is the leading producer of online and offline industry-specific investment conferences for investors and a member of the World Investor Link family of companies serving self-reliant investors.
About World Investor Link: Since 1992, World Investor Link (www.worldinvestorlink.com) has opened information channels from public companies to potential investors. This year World Investor Link will make more than 5 million investor introductions to over 4,600 corporate clients worldwide through services including The Annual Reports Service, The Fund Info Service, Vcall (www.vcall.com), Investor Conference (www.investorconference.com), and Informed Investors Forums (www.informedinvestors.com). World Investor Links' array of products and services enables companies to comply with regulation fair-disclosure requirements by providing investors free access to onsite and Webcast investor events and company financial reports. Mutual funds and companies get visibility with investors at the point investors are making decisions through World Investor Link's relationships with over 160 of the leading financial media channels including The Wall Street Journal, Financial Times, Barron's and Yahoo!Finance. World Investor Link, Inc. a wholly owned subsidiary of WILink.com plc (WLK on The London Stock Exchange) began operations in Richmond, Va., in 1993.